Pharmaceutical and animal health products maker, Ebos Group, has posted a 12 percent increase in first-half profit as it reaps the benefits of a diverse portfolio.

Profit rose to a record $76.7 million in the six months ended December 31, from $68.8 million a year earlier, the Christchurch-based company said on Wednesday.

Total revenue slipped 0.4 per cent to $3.94 billion on lower hepatitis C medicine sales. Earnings before interest, tax, depreciation and amortisation lifted 16 per cent to $138.5 million.

“Our record first-half results are in line with our expectations and reflect a consistent positive momentum across both our healthcare and animal care businesses,” said chief executive Patrick Davies.

The company reiterated that it expects a 10 per cent lift in constant currency, underlying EBITDA for the year. The constant currency forecast strips out any currency swings.

Ebos transformed itself in 2013 with the purchase of Australian pharmaceutical wholesaler and distributor Symbion. It has since bought New Zealand vitamin and herbal tea maker Red Seal, pharmaceuticals firm Zest, Australian pharmacy retailer Good Price Pharmacy Warehouse, the BlackHawk Premium Pet Care pet food business and merged its Australian Chemmart pharmacy chain with rival Terry White Group.

The healthcare and animal products maker bought Australia’s largest provider of outsourced pharmacy services to hospitals, HPS, for A$154m (NZ$165m), in May last year.

“Our major capital projects in both Australia and New Zealand have all seen excellent progress over the period and remain on-track and budget,” Davies said. “These investments are a key part of our strategy to provide the most efficient warehousing and distribution facilities for our expanding portfolio of businesses.”

Ebos shares last traded at $17.16, and have shed 5.3 per cent over the past year.